Academic Journal
Προβολή σε EDS

Cardiovascular Outcomes among New Users of GLP-1 Receptor Agonists Compared with DPP-4 Inhibitors and Sulfonylureas in Kidney Failure.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Cardiovascular Outcomes among New Users of GLP-1 Receptor Agonists Compared with DPP-4 Inhibitors and Sulfonylureas in Kidney Failure.
Συγγραφείς: Catanese B; Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina., Miller C; Department of Medicine, Duke University School of Medicine, Durham, North Carolina., Wolf M; Weill Department of Medicine, Weill Cornell Medicine, New York, New York., Edmonston D; Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Πηγή: Journal of the American Society of Nephrology : JASN [J Am Soc Nephrol] 2026 Sep 01; Vol. 37 (9), pp. 1992-2003. Date of Electronic Publication: 2026 Mar 12.
Τύπος έκδοσης: Journal Article; Comparative Study
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Wolters Kluwer Health, on behalf of the American Society of Nephrology Country of Publication: United States NLM ID: 9013836 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-3450 (Electronic) Linking ISSN: 10466673 NLM ISO Abbreviation: J Am Soc Nephrol Subsets: MEDLINE
Imprint Name(s): Publication: 2023- : Hagerstown, MD : Wolters Kluwer Health, on behalf of the American Society of Nephrology
Original Publication: Baltimore, MD : Williams & Wilkins, c1990-
Ιατρικοί όροι (MeSH): Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use , Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/complications , Sulfonylurea Compounds*/therapeutic use , Cardiovascular Diseases*/prevention & control , Cardiovascular Diseases*/epidemiology , Cardiovascular Diseases*/etiology , Cardiovascular Diseases*/mortality , Hypoglycemic Agents*/therapeutic use , Renal Insufficiency*/complications , Kidney Failure, Chronic*/complications , Glucagon-Like Peptide-1 Receptor Agonists*, United States/epidemiology ; Hospitalization/statistics & numerical data ; Humans ; Male ; Female ; Aged ; Heart Failure ; Aged, 80 and over
Περίληψη: Key Points: Glucagon-like peptide-1 receptor agonists are increasingly used in patients with kidney failure despite trial exclusion. Initiation was associated with a 13% lower risk of cardiovascular events and 17% lower mortality versus dipeptidyl peptidase-4 inhibitors. Initiation was associated with a 10% lower risk of heart failure hospitalization versus dipeptidyl peptidase-4 inhibitors.
Background: Few therapies improve cardiovascular outcomes for people with kidney failure. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduce cardiovascular risk in patients with non-dialysis-dependent CKD, but the cardiovascular benefits in patients with kidney failure remain uncertain. The objective of this study was to compare cardiovascular outcomes among patients with kidney failure and type 2 diabetes newly initiated on GLP-1 RA versus other antiglycemic agents.
Methods: We analyzed electronic health records, Medicare claims, and Part D data from the United States Renal Data System (2011-2021) to identify new users of GLP-1 RA ( n =3629), dipeptidyl peptidase-4 inhibitors (DPP4i; n =21,369), and sulfonylureas ( n =32,296) among patients with type 2 diabetes receiving maintenance dialysis. For the primary analysis, we performed 1:1 propensity score matching of GLP-1 RA to DPP4i initiators using 61 covariates. A prespecified secondary analysis compared propensity score-matched initiators of GLP-1 RA and sulfonylureas. The primary outcome was a modified major adverse cardiovascular event (MACE) composite of myocardial infarction, stroke, or all-cause mortality. Secondary outcomes included the individual components of the primary outcome and hospitalizations for heart failure. Cause-specific Cox models were used to estimate hazard ratios (HRs).
Results: Among 3284 matched pairs of GLP-1 RA and DPP4i initiators, GLP-1 RA use was associated with lower risks of MACE (HR, 0.87; 95% confidence interval [CI], 0.78 to 0.97), all-cause mortality (HR, 0.83; 95% CI, 0.74 to 0.94), and heart failure hospitalization (HR, 0.90; 95% CI, 0.83 to 0.99) over up to 2 years of follow-up. Among 2792 matched pairs, GLP-1 RA and sulfonylurea initiators, GLP-1 RA was associated with lower risks of MACE (HR, 0.83; 95% CI, 0.74 to 0.93) and all-cause mortality (HR, 0.80; 95% CI, 0.69 to 0.91).
Conclusions: Among patients with type 2 diabetes receiving maintenance dialysis, GLP-1 RA initiation was associated with lower risk of cardiovascular events and all-cause mortality compared with other commonly prescribed antiglycemic agents.
Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2026_06_12_ASN0000001061.mp3.
(Copyright © 2026 by the American Society of Nephrology.)
References: J Stat Softw. 2010;33(1):1-22. (PMID: 20808728)
N Engl J Med. 2009 Apr 2;360(14):1395-407. (PMID: 19332456)
Cardiovasc Diabetol. 2022 Oct 3;21(1):200. (PMID: 36199064)
Curr Pharm Des. 2014;20(37):5829-33. (PMID: 24533939)
N Engl J Med. 2019 Jun 13;380(24):2295-2306. (PMID: 30990260)
J Am Coll Cardiol. 2024 Oct 22;84(17):1615-1628. (PMID: 39217553)
J Am Heart Assoc. 2016 Aug 04;5(8):. (PMID: 27491836)
Circulation. 2021 Mar 16;143(11):1157-1172. (PMID: 33720773)
Nephrol Dial Transplant. 2025 Feb 04;40(2):371-384. (PMID: 38986509)
Lancet. 2014 May 24;383(9931):1831-43. (PMID: 24856028)
Clin Pharmacokinet. 2017 Nov;56(11):1381-1390. (PMID: 28349386)
N Engl J Med. 2005 Jul 21;353(3):238-48. (PMID: 16034009)
J Am Heart Assoc. 2024 Feb 20;13(4):e032463. (PMID: 38362889)
N Engl J Med. 2020 Oct 8;383(15):1436-1446. (PMID: 32970396)
Am J Nephrol. 2022;53(1):32-40. (PMID: 35016183)
Kidney Int Rep. 2019 Mar 28;4(6):864-872. (PMID: 31194073)
Diabetes Care. 2016 Feb;39(2):206-13. (PMID: 26283739)
Circulation. 2022 Dec 13;146(24):1882-1894. (PMID: 36508493)
JAMA Netw Open. 2024 Sep 3;7(9):e2433326. (PMID: 39269703)
Diabetes Care. 2025 May 1;48(5):846-859. (PMID: 40156846)
N Engl J Med. 2023 Jan 12;388(2):117-127. (PMID: 36331190)
J Am Heart Assoc. 2020 Jan 7;9(1):e012940. (PMID: 31902326)
J Clin Invest. 2025 Nov 3;135(21):. (PMID: 41178710)
J Card Fail. 2023 Jan;29(1):87-107. (PMID: 36243339)
N Engl J Med. 2020 Dec 03;383(23):2219-2229. (PMID: 33264825)
N Engl J Med. 2024 Jul 11;391(2):109-121. (PMID: 38785209)
Eur Heart J. 2019 Mar 14;40(11):880-886. (PMID: 28431138)
JAMA Netw Open. 2022 Mar 01;5(3):e221169. (PMID: 35254430)
Circ Res. 2022 Mar 4;130(5):694-707. (PMID: 35100822)
Am J Prev Cardiol. 2024 May 07;18:100679. (PMID: 38779187)
Clin J Am Soc Nephrol. 2025 Jun 17;20(8):1100-1110. (PMID: 40526425)
Grant Information: TL1 DK139567 United States DK NIDDK NIH HHS; U2C DK133491 United States DK NIDDK NIH HHS; School of Medicine, Duke University
Contributed Indexing: Keywords: ESKD; GLP-1 receptor agonists; cardiovascular disease; cardiovascular events; diabetes mellitus; heart failure
Substance Nomenclature: 0 (Glucagon-Like Peptide-1 Receptor Agonists)
0 (Dipeptidyl-Peptidase IV Inhibitors)
0 (Sulfonylurea Compounds)
0 (Hypoglycemic Agents)
Entry Date(s): Date Created: 20260312 Date Completed: 20260901 Latest Revision: 20260913
Update Code: 20260913
PubMed Central ID: PMC13240616
DOI: 10.1681/ASN.0000001061
PMID: 41817629
Βάση Δεδομένων: MEDLINE
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/fiv2js/result?sid=EBSCO:cmedm&genre=article&issn=15333450&ISBN=&volume=37&issue=9&date=20260901&spage=1992&pages=1992-2003&title=Journal of the American Society of Nephrology : JASN&atitle=Cardiovascular%20Outcomes%20among%20New%20Users%20of%20GLP-1%20Receptor%20Agonists%20Compared%20with%20DPP-4%20Inhibitors%20and%20Sulfonylureas%20in%20Kidney%20Failure.&aulast=Catanese%20B&id=DOI:10.1681/ASN.0000001061
    Name: Full Text Finder (for New FTF UI) (ns324271)
    Category: fullText
    Text: Full Text Finder
    MouseOverText: Full Text Finder
Header DbId: cmedm
DbLabel: MEDLINE
An: 41817629
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cardiovascular Outcomes among New Users of GLP-1 Receptor Agonists Compared with DPP-4 Inhibitors and Sulfonylureas in Kidney Failure.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Catanese+B%22">Catanese B</searchLink>; Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.<br /><searchLink fieldCode="AU" term="%22Miller+C%22">Miller C</searchLink>; Department of Medicine, Duke University School of Medicine, Durham, North Carolina.<br /><searchLink fieldCode="AU" term="%22Wolf+M%22">Wolf M</searchLink>; Weill Department of Medicine, Weill Cornell Medicine, New York, New York.<br /><searchLink fieldCode="AU" term="%22Edmonston+D%22">Edmonston D</searchLink>; Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229013836%22">Journal of the American Society of Nephrology : JASN</searchLink> [J Am Soc Nephrol] 2026 Sep 01; Vol. 37 (9), pp. 1992-2003. <i>Date of Electronic Publication: </i>2026 Mar 12.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Comparative Study
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wolters+Kluwer+Health%2C+on+behalf+of+the+American+Society+of+Nephrology%22">Wolters Kluwer Health, on behalf of the American Society of Nephrology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9013836 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1533-3450 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210466673%22">10466673 </searchLink><i>NLM ISO Abbreviation: </i>J Am Soc Nephrol <i>Subsets: </i>MEDLINE
– Name: PublisherInfo
  Label: Imprint Name(s)
  Group: PubInfo
  Data: <i>Publication</i>: 2023- : Hagerstown, MD : Wolters Kluwer Health, on behalf of the American Society of Nephrology<br /><i>Original Publication</i>: Baltimore, MD : Williams & Wilkins, c1990-
– Name: SubjectMESH
  Label: MeSH Terms
  Group: Su
  Data: <searchLink fieldCode="MM" term="%22Dipeptidyl-Peptidase+IV+Inhibitors%22">Dipeptidyl-Peptidase IV Inhibitors*</searchLink>/<searchLink fieldCode="MM" term="%22Dipeptidyl-Peptidase+IV+Inhibitors+therapeutic+use%22">therapeutic use</searchLink> <br /><searchLink fieldCode="MM" term="%22Diabetes+Mellitus%2C+Type+2%22">Diabetes Mellitus, Type 2*</searchLink>/<searchLink fieldCode="MM" term="%22Diabetes+Mellitus%2C+Type+2+drug+therapy%22">drug therapy</searchLink> <br /><searchLink fieldCode="MM" term="%22Diabetes+Mellitus%2C+Type+2%22">Diabetes Mellitus, Type 2*</searchLink>/<searchLink fieldCode="MM" term="%22Diabetes+Mellitus%2C+Type+2+complications%22">complications</searchLink> <br /><searchLink fieldCode="MM" term="%22Sulfonylurea+Compounds%22">Sulfonylurea Compounds*</searchLink>/<searchLink fieldCode="MM" term="%22Sulfonylurea+Compounds+therapeutic+use%22">therapeutic use</searchLink> <br /><searchLink fieldCode="MM" term="%22Cardiovascular+Diseases%22">Cardiovascular Diseases*</searchLink>/<searchLink fieldCode="MM" term="%22Cardiovascular+Diseases+prevention+%26+control%22">prevention & control</searchLink> <br /><searchLink fieldCode="MM" term="%22Cardiovascular+Diseases%22">Cardiovascular Diseases*</searchLink>/<searchLink fieldCode="MM" term="%22Cardiovascular+Diseases+epidemiology%22">epidemiology</searchLink> <br /><searchLink fieldCode="MM" term="%22Cardiovascular+Diseases%22">Cardiovascular Diseases*</searchLink>/<searchLink fieldCode="MM" term="%22Cardiovascular+Diseases+etiology%22">etiology</searchLink> <br /><searchLink fieldCode="MM" term="%22Cardiovascular+Diseases%22">Cardiovascular Diseases*</searchLink>/<searchLink fieldCode="MM" term="%22Cardiovascular+Diseases+mortality%22">mortality</searchLink> <br /><searchLink fieldCode="MM" term="%22Hypoglycemic+Agents%22">Hypoglycemic Agents*</searchLink>/<searchLink fieldCode="MM" term="%22Hypoglycemic+Agents+therapeutic+use%22">therapeutic use</searchLink> <br /><searchLink fieldCode="MM" term="%22Renal+Insufficiency%22">Renal Insufficiency*</searchLink>/<searchLink fieldCode="MM" term="%22Renal+Insufficiency+complications%22">complications</searchLink> <br /><searchLink fieldCode="MM" term="%22Kidney+Failure%2C+Chronic%22">Kidney Failure, Chronic*</searchLink>/<searchLink fieldCode="MM" term="%22Kidney+Failure%2C+Chronic+complications%22">complications</searchLink> <br /><searchLink fieldCode="MM" term="%22Glucagon-Like+Peptide-1+Receptor+Agonists%22">Glucagon-Like Peptide-1 Receptor Agonists*</searchLink><br /><searchLink fieldCode="MH" term="%22United+States%22">United States</searchLink>/<searchLink fieldCode="MH" term="%22United+States+epidemiology%22">epidemiology</searchLink> ; <searchLink fieldCode="MH" term="%22Hospitalization%22">Hospitalization</searchLink>/<searchLink fieldCode="MH" term="%22Hospitalization+statistics+%26+numerical+data%22">statistics & numerical data</searchLink> ; <searchLink fieldCode="MH" term="%22Humans%22">Humans</searchLink> ; <searchLink fieldCode="MH" term="%22Male%22">Male</searchLink> ; <searchLink fieldCode="MH" term="%22Female%22">Female</searchLink> ; <searchLink fieldCode="MH" term="%22Aged%22">Aged</searchLink> ; <searchLink fieldCode="MH" term="%22Heart+Failure%22">Heart Failure</searchLink> ; <searchLink fieldCode="MH" term="%22Aged%2C+80+and+over%22">Aged, 80 and over</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Key Points: Glucagon-like peptide-1 receptor agonists are increasingly used in patients with kidney failure despite trial exclusion. Initiation was associated with a 13% lower risk of cardiovascular events and 17% lower mortality versus dipeptidyl peptidase-4 inhibitors. Initiation was associated with a 10% lower risk of heart failure hospitalization versus dipeptidyl peptidase-4 inhibitors.<br />Background: Few therapies improve cardiovascular outcomes for people with kidney failure. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduce cardiovascular risk in patients with non-dialysis-dependent CKD, but the cardiovascular benefits in patients with kidney failure remain uncertain. The objective of this study was to compare cardiovascular outcomes among patients with kidney failure and type 2 diabetes newly initiated on GLP-1 RA versus other antiglycemic agents.<br />Methods: We analyzed electronic health records, Medicare claims, and Part D data from the United States Renal Data System (2011-2021) to identify new users of GLP-1 RA ( n =3629), dipeptidyl peptidase-4 inhibitors (DPP4i; n =21,369), and sulfonylureas ( n =32,296) among patients with type 2 diabetes receiving maintenance dialysis. For the primary analysis, we performed 1:1 propensity score matching of GLP-1 RA to DPP4i initiators using 61 covariates. A prespecified secondary analysis compared propensity score-matched initiators of GLP-1 RA and sulfonylureas. The primary outcome was a modified major adverse cardiovascular event (MACE) composite of myocardial infarction, stroke, or all-cause mortality. Secondary outcomes included the individual components of the primary outcome and hospitalizations for heart failure. Cause-specific Cox models were used to estimate hazard ratios (HRs).<br />Results: Among 3284 matched pairs of GLP-1 RA and DPP4i initiators, GLP-1 RA use was associated with lower risks of MACE (HR, 0.87; 95% confidence interval [CI], 0.78 to 0.97), all-cause mortality (HR, 0.83; 95% CI, 0.74 to 0.94), and heart failure hospitalization (HR, 0.90; 95% CI, 0.83 to 0.99) over up to 2 years of follow-up. Among 2792 matched pairs, GLP-1 RA and sulfonylurea initiators, GLP-1 RA was associated with lower risks of MACE (HR, 0.83; 95% CI, 0.74 to 0.93) and all-cause mortality (HR, 0.80; 95% CI, 0.69 to 0.91).<br />Conclusions: Among patients with type 2 diabetes receiving maintenance dialysis, GLP-1 RA initiation was associated with lower risk of cardiovascular events and all-cause mortality compared with other commonly prescribed antiglycemic agents.<br />Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2026_06_12_ASN0000001061.mp3.<br /> (Copyright © 2026 by the American Society of Nephrology.)
– Name: Ref
  Label: References
  Group: RefInfo
  Data: J Stat Softw. 2010;33(1):1-22. (PMID: <searchLink fieldCode="PM" term="%2220808728%22">20808728)</searchLink><br />N Engl J Med. 2009 Apr 2;360(14):1395-407. (PMID: <searchLink fieldCode="PM" term="%2219332456%22">19332456)</searchLink><br />Cardiovasc Diabetol. 2022 Oct 3;21(1):200. (PMID: <searchLink fieldCode="PM" term="%2236199064%22">36199064)</searchLink><br />Curr Pharm Des. 2014;20(37):5829-33. (PMID: <searchLink fieldCode="PM" term="%2224533939%22">24533939)</searchLink><br />N Engl J Med. 2019 Jun 13;380(24):2295-2306. (PMID: <searchLink fieldCode="PM" term="%2230990260%22">30990260)</searchLink><br />J Am Coll Cardiol. 2024 Oct 22;84(17):1615-1628. (PMID: <searchLink fieldCode="PM" term="%2239217553%22">39217553)</searchLink><br />J Am Heart Assoc. 2016 Aug 04;5(8):. (PMID: <searchLink fieldCode="PM" term="%2227491836%22">27491836)</searchLink><br />Circulation. 2021 Mar 16;143(11):1157-1172. (PMID: <searchLink fieldCode="PM" term="%2233720773%22">33720773)</searchLink><br />Nephrol Dial Transplant. 2025 Feb 04;40(2):371-384. (PMID: <searchLink fieldCode="PM" term="%2238986509%22">38986509)</searchLink><br />Lancet. 2014 May 24;383(9931):1831-43. (PMID: <searchLink fieldCode="PM" term="%2224856028%22">24856028)</searchLink><br />Clin Pharmacokinet. 2017 Nov;56(11):1381-1390. (PMID: <searchLink fieldCode="PM" term="%2228349386%22">28349386)</searchLink><br />N Engl J Med. 2005 Jul 21;353(3):238-48. (PMID: <searchLink fieldCode="PM" term="%2216034009%22">16034009)</searchLink><br />J Am Heart Assoc. 2024 Feb 20;13(4):e032463. (PMID: <searchLink fieldCode="PM" term="%2238362889%22">38362889)</searchLink><br />N Engl J Med. 2020 Oct 8;383(15):1436-1446. (PMID: <searchLink fieldCode="PM" term="%2232970396%22">32970396)</searchLink><br />Am J Nephrol. 2022;53(1):32-40. (PMID: <searchLink fieldCode="PM" term="%2235016183%22">35016183)</searchLink><br />Kidney Int Rep. 2019 Mar 28;4(6):864-872. (PMID: <searchLink fieldCode="PM" term="%2231194073%22">31194073)</searchLink><br />Diabetes Care. 2016 Feb;39(2):206-13. (PMID: <searchLink fieldCode="PM" term="%2226283739%22">26283739)</searchLink><br />Circulation. 2022 Dec 13;146(24):1882-1894. (PMID: <searchLink fieldCode="PM" term="%2236508493%22">36508493)</searchLink><br />JAMA Netw Open. 2024 Sep 3;7(9):e2433326. (PMID: <searchLink fieldCode="PM" term="%2239269703%22">39269703)</searchLink><br />Diabetes Care. 2025 May 1;48(5):846-859. (PMID: <searchLink fieldCode="PM" term="%2240156846%22">40156846)</searchLink><br />N Engl J Med. 2023 Jan 12;388(2):117-127. (PMID: <searchLink fieldCode="PM" term="%2236331190%22">36331190)</searchLink><br />J Am Heart Assoc. 2020 Jan 7;9(1):e012940. (PMID: <searchLink fieldCode="PM" term="%2231902326%22">31902326)</searchLink><br />J Clin Invest. 2025 Nov 3;135(21):. (PMID: <searchLink fieldCode="PM" term="%2241178710%22">41178710)</searchLink><br />J Card Fail. 2023 Jan;29(1):87-107. (PMID: <searchLink fieldCode="PM" term="%2236243339%22">36243339)</searchLink><br />N Engl J Med. 2020 Dec 03;383(23):2219-2229. (PMID: <searchLink fieldCode="PM" term="%2233264825%22">33264825)</searchLink><br />N Engl J Med. 2024 Jul 11;391(2):109-121. (PMID: <searchLink fieldCode="PM" term="%2238785209%22">38785209)</searchLink><br />Eur Heart J. 2019 Mar 14;40(11):880-886. (PMID: <searchLink fieldCode="PM" term="%2228431138%22">28431138)</searchLink><br />JAMA Netw Open. 2022 Mar 01;5(3):e221169. (PMID: <searchLink fieldCode="PM" term="%2235254430%22">35254430)</searchLink><br />Circ Res. 2022 Mar 4;130(5):694-707. (PMID: <searchLink fieldCode="PM" term="%2235100822%22">35100822)</searchLink><br />Am J Prev Cardiol. 2024 May 07;18:100679. (PMID: <searchLink fieldCode="PM" term="%2238779187%22">38779187)</searchLink><br />Clin J Am Soc Nephrol. 2025 Jun 17;20(8):1100-1110. (PMID: <searchLink fieldCode="PM" term="%2240526425%22">40526425)</searchLink>
– Name: GrantInfo
  Label: Grant Information
  Group: Grant
  Data: TL1 DK139567 United States DK NIDDK NIH HHS; U2C DK133491 United States DK NIDDK NIH HHS; School of Medicine, Duke University
– Name: SubjectMinor
  Label: Contributed Indexing
  Group:
  Data: <i>Keywords: </i>ESKD; GLP-1 receptor agonists; cardiovascular disease; cardiovascular events; diabetes mellitus; heart failure
– Name: NumberCAS
  Label: Substance Nomenclature
  Group: ID
  Data: 0 (Glucagon-Like Peptide-1 Receptor Agonists)<br />0 (Dipeptidyl-Peptidase IV Inhibitors)<br />0 (Sulfonylurea Compounds)<br />0 (Hypoglycemic Agents)
– Name: DateEntry
  Label: Entry Date(s)
  Group: Date
  Data: <i>Date Created: </i>20260312 <i>Date Completed: </i>20260901 <i>Latest Revision: </i>20260913
– Name: DateUpdate
  Label: Update Code
  Group: Date
  Data: 20260913
– Name: PubmedCentralID
  Label: PubMed Central ID
  Group: ID
  Data: PMC13240616
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1681/ASN.0000001061
– Name: AN
  Label: PMID
  Group: ID
  Data: 41817629
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cmedm&AN=41817629
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1681/ASN.0000001061
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1992
    Subjects:
      – SubjectFull: United States epidemiology
        Type: general
      – SubjectFull: Hospitalization statistics & numerical data
        Type: general
      – SubjectFull: Humans
        Type: general
      – SubjectFull: Male
        Type: general
      – SubjectFull: Female
        Type: general
      – SubjectFull: Aged
        Type: general
      – SubjectFull: Heart Failure
        Type: general
      – SubjectFull: Aged, 80 and over
        Type: general
      – SubjectFull: Dipeptidyl-Peptidase IV Inhibitors therapeutic use
        Type: general
      – SubjectFull: Diabetes Mellitus, Type 2 drug therapy
        Type: general
      – SubjectFull: Diabetes Mellitus, Type 2 complications
        Type: general
      – SubjectFull: Sulfonylurea Compounds therapeutic use
        Type: general
      – SubjectFull: Cardiovascular Diseases prevention & control
        Type: general
      – SubjectFull: Cardiovascular Diseases epidemiology
        Type: general
      – SubjectFull: Cardiovascular Diseases etiology
        Type: general
      – SubjectFull: Cardiovascular Diseases mortality
        Type: general
      – SubjectFull: Hypoglycemic Agents therapeutic use
        Type: general
      – SubjectFull: Renal Insufficiency complications
        Type: general
      – SubjectFull: Kidney Failure, Chronic complications
        Type: general
      – SubjectFull: Glucagon-Like Peptide-1 Receptor Agonists
        Type: general
    Titles:
      – TitleFull: Cardiovascular Outcomes among New Users of GLP-1 Receptor Agonists Compared with DPP-4 Inhibitors and Sulfonylureas in Kidney Failure.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Catanese B
      – PersonEntity:
          Name:
            NameFull: Miller C
      – PersonEntity:
          Name:
            NameFull: Wolf M
      – PersonEntity:
          Name:
            NameFull: Edmonston D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2026 Sep 01
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1533-3450
          Numbering:
            – Type: volume
              Value: 37
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Journal of the American Society of Nephrology : JASN
              Type: main
ResultId 1